United States Patent 8,470,842: Aprepitant Crystalline Form I Patent Scope, Expiration, Litigation and Generic-Entry Risk
US Patent No. 8,470,842 protects methods of using a specific crystalline form of aprepitant, the active ingredient in Merck’s Emend antiemetic products. The patent does not broadly claim aprepitant, all aprepitant formulations, or the chemical compound itself. Its claims are directed to administering crystalline Form I monohydrate hydrochloride aprepitant, identified by specified powder X-ray diffraction characteristics, to treat or delay nausea and emesis.
The patent’s principal commercial value was protection against use of the claimed solid form in chemotherapy-induced nausea and vomiting regimens, particularly in combination with temozolomide, 5-HT3 antagonists and dexamethasone. Its nominal patent term runs to December 2025, subject to any patent-term adjustment recorded by the USPTO.
What drug and solid form does US 8,470,842 protect?
US 8,470,842 covers aprepitant, a neurokinin-1, or NK1, receptor antagonist. Aprepitant is marketed orally as Emend and is also used as the active moiety in the intravenous prodrug fosaprepitant.
The patented material is not merely aprepitant in any physical form. It is:
- A crystalline Form I material;
- A monohydrate;
- A hydrochloride salt;
- The stereochemically defined aprepitant compound; and
- A solid form characterized by specified X-ray powder diffraction peaks.
The independent claims require administration of a medicament containing the claimed crystalline form. The strongest structural limitation is the X-ray diffraction profile. Claim 1 requires at least a strong peak at approximately 21.6 degrees two-theta, corresponding to a lattice spacing of approximately 4.11 angstroms.
The claims identify the compound through its systematic chemical name rather than the generic name aprepitant:
(5S,8S)-8-[{(1R)-1-(3,5-bis-trifluoromethyl)phenyl-ethoxy}methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one.
| Patent element |
Scope |
| Active ingredient |
Aprepitant |
| Salt |
Hydrochloride |
| Hydration state |
Monohydrate |
| Solid form |
Crystalline Form I |
| Analytical limitation |
Specified PXRD peaks |
| Primary indication |
Nausea and emesis, including chemotherapy-induced symptoms |
| Combination therapy |
Chemotherapeutic agents, 5-HT3 inhibitors and corticosteroids |
| Named chemotherapy |
Temozolomide |
| Patent type |
Method-of-treatment and polymorph-specific patent |
What do the claims of US 8,470,842 cover?
Claims 1 and 10 are the principal independent claims.
Claim 1 covers treating or delaying chemotherapy-induced nausea or emesis in a mammal by administering a medicament containing the claimed crystalline Form I monohydrate hydrochloride salt. The claim requires chemotherapy exposure but does not require a particular chemotherapeutic agent.
Claim 10 is broader as to the cause of nausea and emesis. It covers treating or delaying nausea or emesis generally, using the same crystalline form and a PXRD pattern substantially as shown in Figure 1.
Claims 2 through 6 add combination-treatment limitations. Claims 3 and 6 specifically identify temozolomide. Claims 4, 11, 12 and 13 cover use with additional therapeutic agents, including:
- 5-HT3 inhibitors;
- Ondansetron;
- Granisetron;
- Palonosetron;
- Dolasetron;
- Tropisetron; and
- Dexamethasone.
Claims 14 through 16 define administration before, during or after chemotherapy. These claims target treatment regimens rather than a particular capsule composition or manufacturing process.
Claims 7 through 9 narrow the PXRD requirements. They require one or more additional peaks at approximately 16.1, 18.4 and 23.5 degrees two-theta. Claim 9 requires all four identified peaks:
| Two-theta angle |
Relative intensity |
Lattice spacing |
| 16.1 ± 0.2° |
Medium |
5.49 ± 0.04 Å |
| 18.4 ± 0.2° |
Medium |
4.83 ± 0.04 Å |
| 21.6 ± 0.2° |
Strong |
4.11 ± 0.04 Å |
| 23.5 ± 0.2° |
Medium |
3.78 ± 0.04 Å |
The use of “comprising” makes the claims open-ended. A medicament may contain additional ingredients, and a treatment regimen may include other therapeutic agents. The accused product or use must still satisfy the required salt, hydration, crystalline-form and diffraction limitations.
How strong is the patent estate for aprepitant?
The patent estate has several distinct layers:
- Compound patents covering aprepitant as a chemical entity.
- Therapeutic-use patents covering antiemetic treatment.
- Formulation patents covering oral dosage forms or delivery systems.
- Solid-state patents covering crystalline or solvated forms.
- Prodrug patents covering fosaprepitant.
- Method-of-use patents covering treatment timing and combination regimens.
US 8,470,842 is in the fourth and sixth categories. It is narrower than a basic compound patent but potentially more difficult to design around if the marketed product or manufacturing process necessarily produces the claimed Form I monohydrate hydrochloride material.
The patent does not appear, from the claim language supplied, to cover:
- Any noncrystalline aprepitant;
- An amorphous aprepitant form;
- A different polymorph;
- A different hydrate or solvate;
- A free-base aprepitant;
- A non-hydrochloride salt;
- Fosaprepitant as such;
- A method that does not administer the claimed crystalline form; or
- A formulation that contains no detectable amount of the claimed form.
The central validity and infringement issue is therefore solid-form identity. PXRD testing, hydration analysis, salt characterization and batch-to-batch manufacturing records would be central in a dispute.
When does US 8,470,842 expire?
The patent claims priority to a December 2004 filing date associated with the crystalline aprepitant invention. Under the Uruguay Round Agreements Act, the nominal term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and any terminal disclaimer.
| Event |
Date or period |
| Earliest priority period |
December 2004 |
| US patent issuance |
June 25, 2013 |
| Nominal 20-year expiration |
December 2025 |
| Potential adjustment |
Any USPTO-recorded patent-term adjustment |
| Patent type |
Small-molecule method and solid-form patent |
The practical exclusivity date should be taken from the USPTO patent record rather than calculated solely from the priority date. Patent-term adjustment can move the expiration date beyond the nominal date. Patent-term extension under 35 U.S.C. §156 is generally associated with regulatory review of an approved product and must be distinguished from ordinary patent-term adjustment.
What is the FDA regulatory and Orange Book status?
Emend, containing aprepitant, was approved by the FDA in 2003 under NDA 021549 for prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. The label later covered moderately emetogenic chemotherapy and combination use with a corticosteroid and a 5-HT3 antagonist.[2]
FDA approval does not itself establish infringement of US 8,470,842. The patent is infringed only if the approved use and supplied drug satisfy the issued claim limitations.
The Orange Book may list patents associated with the Emend NDA, including patents directed to drug substance, formulations and approved methods of use. An Orange Book listing provides statutory notice and affects abbreviated new drug application, or ANDA, certification procedures. It does not determine the ultimate validity or infringement of a patent.
For US 8,470,842, the relevant regulatory question is whether the patent was listed against the applicable Emend NDA and whether the listed claims correspond to an FDA-approved method of use. A polymorph patent may also raise an Orange Book listing issue if the listed claims cover the drug product or an approved use in a manner recognized under FDA listing regulations.
Which companies challenged the aprepitant patent estate?
Generic applicants challenged the broader Emend patent estate through Paragraph IV certifications and related litigation. Publicly reported aprepitant litigation has involved generic manufacturers seeking approval for oral aprepitant products, including Teva and other ANDA sponsors.
The important distinction is between:
- Challenges to compound patents;
- Challenges to formulation or dosage-form patents;
- Challenges to method-of-use patents; and
- Challenges to crystalline-form patents.
A Paragraph IV certification against one Emend patent does not automatically invalidate or remove US 8,470,842. Each patent requires a separate invalidity and noninfringement analysis. Potential defenses include:
- The generic product contains a different polymorph;
- The product is not the claimed monohydrate hydrochloride form;
- The relevant PXRD peaks are absent or outside the claimed ranges;
- The claims are anticipated by prior-art solid forms;
- The claims would have been obvious in view of known aprepitant salts and hydrates;
- The claims lack enablement or written description; or
- The asserted use is not an approved or infringing method of treatment.
The supplied claim set does not establish that US 8,470,842 itself was finally invalidated, disclaimed or adjudicated unenforceable. A litigation docket and USPTO maintenance record are required to state a final case-specific outcome.
What patent litigation affects generic aprepitant entry?
Generic entry depends on the entire remaining patent and regulatory barrier, not on US 8,470,842 alone.
For oral aprepitant, the main entry pathways are:
- A Paragraph III certification accepting delayed entry until relevant patents expire.
- A Paragraph IV certification alleging invalidity or noninfringement.
- A settlement permitting entry on a negotiated date.
- An ANDA approval after expiration or delisting of blocking patents.
- A product design that avoids the claimed crystalline form or approved method.
A generic manufacturer can face different risks depending on whether it sells:
- Aprepitant capsules;
- Orally disintegrating tablets;
- A liquid formulation;
- Intravenous fosaprepitant;
- A combination antiemetic product; or
- A product labeled for a narrower indication.
The claims in US 8,470,842 create the greatest risk for a generic whose product uses the same Form I monohydrate hydrochloride aprepitant and whose label directs use for chemotherapy-induced nausea or emesis. A “skinny label” may reduce method-of-use risk but cannot eliminate liability if the product is marketed for the patented use or if the patented use is unavoidable in practice.
What formulation and manufacturing barriers remain?
The patent claims do not directly recite capsule excipients, particle size, granulation, coating, dissolution specifications or a particular manufacturing process. Its practical manufacturing significance is different: the crystallization process determines whether the finished active pharmaceutical ingredient is the claimed Form I monohydrate hydrochloride.
A design-around may involve:
- A different polymorph;
- An amorphous solid;
- A non-hydrated form;
- A different salt;
- A different crystallization route that produces a non-infringing form; or
- A formulation that converts the active ingredient before administration.
Each design-around must be tested against the claims and against other members of the aprepitant patent estate. Avoiding US 8,470,842 may increase exposure to another solid-form or formulation patent.
How does aprepitant compare with competing antiemetic drugs?
| Product |
Active ingredient |
Mechanism or class |
Patent and entry profile |
| Emend |
Aprepitant |
NK1 antagonist |
Oral generic competition; solid-form and method patents historically relevant |
| Fosaprepitant |
Fosaprepitant dimeglumine |
IV prodrug of aprepitant |
Separate product and formulation estate |
| Akynzeo |
Netupitant/palonosetron |
NK1 plus 5-HT3 blockade |
Combination-product and formulation protection |
| Varubi |
Rolapitant |
NK1 antagonist |
Competing NK1 product; distinct patent estate |
| Zofran and generics |
Ondansetron |
5-HT3 antagonist |
Older generic product |
| Aloxi and generics |
Palonosetron |
Long-acting 5-HT3 antagonist |
Separate compound and formulation estate |
Aprepitant is often used with dexamethasone and a 5-HT3 antagonist. That combination increases clinical overlap with Akynzeo but does not create patent identity between the products.
Biosimilar risk is immaterial. Aprepitant is a chemically synthesized small molecule, not a biologic. The relevant competitors are generics, authorized generics and alternative small-molecule antiemetics.
What is the commercial exposure from US 8,470,842?
The patent’s commercial exposure was tied to Emend oral sales and to the ability to maintain differentiated antiemetic pricing before generic aprepitant entry. Merck reported Emend as a significant pharmaceutical product during the period when chemotherapy-induced nausea and vomiting treatment had limited generic competition.[4]
The patent does not independently protect all Emend revenue. Commercial exposure depends on:
- Whether the marketed product uses the claimed crystalline form;
- Whether other Emend patents remain enforceable;
- Whether generic applicants can enter with a different solid form;
- Whether the generic label includes the patented chemotherapy uses;
- Whether physicians continue using aprepitant in combination regimens; and
- Whether fosaprepitant and competing NK1 products substitute for oral aprepitant.
After generic entry, the principal economic effect of US 8,470,842 is defensive. It may affect the timing, formulation and labeling strategy of an ANDA product, but it is unlikely to preserve exclusivity over the entire aprepitant market once core compound and formulation barriers have expired.
Key Takeaways
- US 8,470,842 is a narrow aprepitant patent focused on a crystalline Form I monohydrate hydrochloride salt.
- The independent claims require administration of the specified crystalline material, not merely aprepitant.
- Claim 1 targets chemotherapy-induced nausea and emesis; claim 10 covers nausea and emesis more generally.
- Temozolomide, 5-HT3 antagonists and dexamethasone are expressly covered in dependent claims.
- PXRD identity is the central infringement and design-around issue.
- The patent’s nominal expiration is December 2025, subject to USPTO-recorded patent-term adjustment.
- Generic risk depends on the entire Emend patent estate and the ANDA applicant’s Paragraph IV, Paragraph III or settlement position.
- Biosimilar analysis is not relevant because aprepitant is a small-molecule drug.
- Fosaprepitant and competing NK1 antagonists have separate patent and regulatory estates.
- The patent does not by itself block every aprepitant formulation, salt, polymorph or method of use.
FAQs
Does US 8,470,842 cover the active pharmaceutical ingredient aprepitant?
No. It covers methods using a specific crystalline Form I monohydrate hydrochloride salt of aprepitant. Broad compound protection must be analyzed under separate aprepitant patents.
Can a generic avoid US 8,470,842 by using amorphous aprepitant?
Potentially, if the product does not contain the claimed crystalline Form I monohydrate hydrochloride and no other patent is infringed. Analytical testing and the complete patent estate remain decisive.
Does a patent on aprepitant’s polymorph block fosaprepitant?
Not necessarily. Fosaprepitant is a separate prodrug and is subject to its own composition, formulation and method-of-use claims.
Are claims 14 through 16 separate treatment inventions?
They are dependent claims directed to administration before, during or after chemotherapy. Their enforceability depends on satisfying the underlying claim 5 requirements as well as the timing limitation.
Can a Paragraph IV challenge against another Emend patent defeat US 8,470,842?
No. A Paragraph IV certification is patent-specific. A challenge to a compound or formulation patent does not automatically invalidate or avoid this crystalline-form method patent.
References
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,470,842, Crystalline form of aprepitant.
- U.S. Food and Drug Administration. (2024). Emend (aprepitant) prescribing information. Merck & Co.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Merck & Co., Inc. (2013). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- 35 U.S.C. §§ 154, 156 and 271.
- 21 C.F.R. § 314.53.
